NCT02171572CompletedPhase 1
Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 28
- Primary Endpoint
- Changes in physical examination
Study Overview
Brief Summary
The objective of the current study is to investigate safety, tolerability and, pharmacokinetics of dabigatran etexilate following oral administration of single and multiple oral doses (110mg, 150 mg b.i.d., 7 days) in healthy Chinese subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy subjects according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR and body temperature), 12-lead ECG, clinical laboratory tests
- •No finding of clinical relevance.
- •No evidence of a clinically relevant concomitant disease.
- •Age: ≥18 and ≤45 years.
- •Body Mass Index (BMI): ≥18 and <25 kg/m
- •Signed and dated written informed consent prior to admission to the trial in accordance with Chinese GCP.
Exclusion Criteria
- •Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- •Subject can not use an adequate form of contraception from the time of the first dose on Day 1 up to end-of study examination.
- •Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders.
- •History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts.
- •Chronic or relevant acute infections.
- •History of
- •allergy/hypersensitivity (including drug allergy) which was deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever)
- •any bleeding disorder including prolonged or habitual bleeding
- •other hematologic diseases.
- •cerebral bleeding (e.g. after a car accident).
- •concussions (head trauma resulting in injuring to brain) with or without loss of consciousness.
- •Intake of drugs with a long half-life (> 24 hours) within at least 1 month or less than 10 half-lives, whichever was shorter, of the respective drug prior to administration or during the trial.
- •Use of aspirin (including over-the-counter medications), antiplatelet agents like ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAID), coumadin like anticoagulants, chronic use of corticosteroids, heparin or fibrinolytic agents within 14 days prior to administration up to end-of-study examination.
- •Participation in another trial with an investigational drug within 3 months prior to administration up to end-of-study examination.
- •Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial).
- •Alcohol abuse (more than 60 g/day; confirmed by interview).
- •Drug abuse (confirmed by interview).
- •Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination).
- •Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination).
- •Any laboratory value outside the reference range that is of clinical relevance.
- •Known hypersensitivity to the investigational drug or its excipients.
- •Subject who was judged ineligible by the investigator or the sub-investigator.
- •History of any familial bleeding disorder.
- •Thrombocytes < 100×109 .
- •Pregnant female subjects.
Arms & Interventions
Dabigatran etexilate low
Experimental
Intervention: Dabigatran etexilate low (Drug)
Dabigatran etexilate high
Experimental
Intervention: Dabigatran etexilate high (Drug)
Outcomes
Primary Outcomes
Changes in physical examination
Time Frame: Day 1 and 14
Changes in 12-lead electrocardiogram (ECG)
Time Frame: Day 1, Day 4-10, day 14
Changes from baseline in laboratory examinations
Time Frame: Day 1, 2, 4, 7, 11, 14
Changes in vital signs
Time Frame: Day 1 to 14
Occurrence of adverse events
Time Frame: up to 7 days after last drug intake
Secondary Outcomes
- tmax (time from dosing to maximum measured concentration of the analyte in plasma)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on Day 1)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- Cmax (maximum measured concentration of the analyte in plasma)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- MRTpo, (mean residence time of the analyte in the body after oral administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- AUC0-∞ (amount of analyte that is eliminated in area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- λz (terminal rate constant in plasma)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- t1/2, (terminal half-life of the analyte in plasma)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- CL/F, (apparent clearance of the analyte in plasma following extravascular administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after single dose of study drug)
- tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- λz,ss (terminal rate constant in plasma at steady state)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- t1/2,ss (terminal half-life of the analyte in plasma at steady state)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- RA,Cmax, (calculated as Cmax,ss/Cmax)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- RA,AUC, (calculated as AUCτ,ss/AUCτ,1)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
- linearity index (LI)(Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after last multiple dose of study drug)
Investigators
Similar Trials
Completed
Phase 1
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48
Completed
Phase 2
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer's DiseaseNCT01661673FORUM Pharmaceuticals Inc52
Completed
Phase 1
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy AdultsHealthyNCT01050127Abbott36
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsHealthyNCT02173665Boehringer Ingelheim64
Completed
Phase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly SubjectsHealthyNCT00968422Abbott28